Overview: NGS Alkaptonuria Sequencing TestIntroduction: The NGS Alkaptonuria Sequencing Test sequences genes to diagnose alkaptonuria, causing joint pain or dark urine. Following 2023 NORD guidelines, it uses PCR for high specificity, supporting metabolic screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected alkaptonuria.
Other Names: Alkaptonuria Assay, HGD Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Alkaptonuria sequencing began in the 1990s with metabolic disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose alkaptonuria, guides treatment, and evaluates patients with joint pain or dark urine.
Test Parameters: 1. Alkaptonuria Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of joint pain, dark urine, or alkaptonuria symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document joint pain, dark urine, ochronosis, or family history of alkaptonuria. Include current medications, especially pain relievers.
Consent: Written consent required, detailing the tests purpose, alkaptonuria implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze alkaptonuria genes (e.g., HGD). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for alkaptonuria diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm alkaptonuria, guiding supportive care or nitisinone therapy. Negative results may require urine homogentisic acid testing.
Specialist Consultation: Consult a geneticist or metabolic specialist for result interpretation and treatment planning.
Additional Supporting Tests: Urine homogentisic acid, joint imaging, or renal function tests to confirm alkaptonuria diagnosis.
Test Limitations: Not all alkaptonuria cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: NORD Alkaptonuria Guidelines, 2023; Journal of Inherited Metabolic Disease, Phornphutkul C, 2022.
